Guojun Zhang Selected Research

Triple Negative Breast Neoplasms

1/2022	Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
1/2020	Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
12/2018	Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
1/2015	Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guojun Zhang Research Topics

Disease

52	Neoplasms (Cancer) 10/2022 - 04/2012
22	Epilepsy (Aura) 03/2022 - 04/2005
19	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 04/2014
16	Lung Neoplasms (Lung Cancer) 01/2020 - 10/2013
15	Drug Resistant Epilepsy 05/2022 - 04/2005
15	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2013
12	Seizures (Absence Seizure) 08/2021 - 01/2004
12	Carcinogenesis 11/2018 - 11/2014
11	Adenocarcinoma of Lung 01/2021 - 12/2014
9	Breast Neoplasms (Breast Cancer) 01/2022 - 04/2012
8	Temporal Lobe Epilepsy 03/2022 - 11/2006
8	Carcinoma (Carcinomatosis) 01/2022 - 06/2013
7	Inflammation (Inflammations) 12/2021 - 01/2013
6	Glioma (Gliomas) 07/2022 - 01/2012
6	Ischemic Stroke 12/2021 - 01/2019
6	Lymphatic Metastasis 01/2021 - 10/2013
6	Urinary Bladder Neoplasms (Bladder Cancer) 12/2017 - 10/2013
4	Meningitis 01/2022 - 10/2020
4	Triple Negative Breast Neoplasms 01/2022 - 01/2015
4	Idiopathic Pulmonary Fibrosis 12/2021 - 06/2014
4	Asthma (Bronchial Asthma) 12/2021 - 02/2020
4	Infections 01/2021 - 09/2011
3	Disease Progression 10/2022 - 01/2021
3	Brain Neoplasms (Brain Tumor) 07/2022 - 01/2020
3	Guillain-Barre Syndrome 01/2022 - 08/2015
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 01/2019
3	Pituitary Neoplasms (Pituitary Adenoma) 01/2021 - 01/2018
3	Partial Epilepsies (Epilepsy, Partial) 01/2021 - 11/2013
3	Leukemia 01/2018 - 07/2012
2	Glioblastoma (Glioblastoma Multiforme) 07/2022 - 01/2020
2	COVID-19 03/2022 - 11/2020
2	Tuberous Sclerosis (Bourneville's Disease) 03/2022 - 01/2022
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2021
2	Diarrhea 01/2022 - 12/2021
2	Pneumonia (Pneumonitis) 10/2021 - 05/2019
2	Multiple Myeloma 01/2021 - 08/2013
2	Sepsis (Septicemia) 01/2020 - 05/2019
2	Chronic Obstructive Pulmonary Disease (COPD) 08/2019 - 05/2018
2	Aseptic Meningitis 01/2019 - 01/2015
2	Bacterial Meningitis 01/2019 - 01/2015
2	Acromegaly 10/2018 - 01/2018
2	Pulmonary Embolism 05/2018 - 12/2014

Drug/Important Bio-Agent (IBA)

19	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2012
15	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2004
15	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2012
13	Long Noncoding RNAIBA 01/2021 - 01/2015
9	Messenger RNA (mRNA)IBA 01/2019 - 04/2005
8	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 01/2015
7	Pharmaceutical PreparationsIBA 01/2022 - 10/2005
6	Biological ProductsIBA 08/2020 - 10/2013
5	Circular RNAIBA 01/2022 - 11/2018
4	ProcalcitoninIBA 12/2021 - 01/2015
4	RNA (Ribonucleic Acid)IBA 12/2021 - 02/2017
4	Small Interfering RNA (siRNA)IBA 01/2021 - 04/2016
4	Polo-Like Kinase 1IBA 12/2017 - 06/2013
3	LipopolysaccharidesIBA 12/2021 - 11/2018
3	Bevacizumab (Avastin)FDA Link 12/2021 - 12/2014
3	Anticonvulsants (Antiepileptic Drugs)IBA 08/2021 - 06/2017
3	EnzymesIBA 04/2021 - 04/2012
3	Lactic Acid (Lactate)FDA LinkGeneric 04/2021 - 01/2015
3	Interleukin-6 (Interleukin 6)IBA 11/2020 - 01/2013
3	Phosphotransferases (Kinase)IBA 10/2020 - 12/2019
3	Carcinoembryonic AntigenIBA 03/2018 - 01/2014
3	AntigensIBA 03/2017 - 01/2014
3	scytoneminIBA 10/2013 - 06/2013
2	trans-sodium crocetinate (crocetin)IBA 03/2022 - 01/2022
2	Coloring Agents (Dyes)IBA 01/2022 - 09/2015
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2021
2	aumolertinibIBA 01/2022 - 01/2022
2	Interleukin-13IBA 12/2021 - 02/2020
2	SteroidsIBA 12/2021 - 11/2017
2	C-Reactive ProteinIBA 12/2021 - 11/2020
2	Nucleic AcidsIBA 12/2021 - 11/2020
2	PerforinIBA 11/2021 - 12/2016
2	Granzymes (Granzyme)IBA 11/2021 - 12/2016
2	OvalbuminIBA 10/2021 - 02/2020
2	Competitive Endogenous RNAIBA 01/2021 - 01/2020
2	CytokinesIBA 01/2021 - 01/2021
2	Enterotoxins (Enterotoxin)IBA 01/2021 - 06/2013
2	SuperantigensIBA 01/2021 - 06/2013
2	Peptides (Polypeptides)IBA 01/2021 - 02/2017
2	CollagenIBA 02/2020 - 01/2015
2	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 11/2018
2	Interleukin-8 (Interleukin 8)IBA 08/2019 - 01/2019
2	Indicators and Reagents (Reagents)IBA 01/2019 - 02/2017
2	Peptide Hydrolases (Proteases)FDA Link 01/2019 - 07/2014
2	Sincalide FDA Link 01/2019 - 06/2013
2	Carrier Proteins (Binding Protein)IBA 01/2019 - 06/2016
2	ImmunosorbentsIBA 03/2018 - 04/2012

Therapy/Procedure

26	Therapeutics 10/2022 - 06/2013
10	Vagus Nerve Stimulation 11/2021 - 01/2020
7	Electrodes (Electrode) 06/2022 - 11/2013
6	Drug Therapy (Chemotherapy) 01/2021 - 01/2018
3	Radiotherapy 07/2022 - 07/2014
3	Immunotherapy 11/2021 - 12/2016
3	Deep Brain Stimulation 08/2021 - 01/2018
3	Craniotomy 08/2021 - 11/2020
3	Adjuvant Chemotherapy 01/2020 - 03/2015
2	Neoadjuvant Therapy 08/2019 - 01/2017
2	Anterior Temporal Lobectomy 10/2018 - 01/2018